Neogap Therapeutics A/S partners with Cellerys AG
Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Dutch State to sell share capital of Intravacc BV
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
EU to decarbonise aviation sector through green fuel targets
The European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
Syngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
Phialogics AG has got a 600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
Forbion raises 1.35bn across two funds
European life sciences venture capital company Forbion has raised two oversubscribed funds totalling 1.35 bn.
Ariceum Therapeutics extends Series A to 47.75m
German radiopharmaceuticals developer Ariceum Therapeutics has raised a further 22.75m extension of its 25m Series A financing announced in June 2022.